This case report details the development of cardiogenic shock after craniotomy in a patient sedated with a propofol infusion. The patient survived with the assistance of extracorporeal membrane oxygenation. A literature review summarizes the syndrome of cardiogenic shock associated with prolonged propofol infusion. This is the first report of survival in this syndrome resulting from mechanical circulatory support. (Anesth Analg 2004;99:221-6) P ropofol is one of the commonly accepted drugs administered as an infusion for the sedation of adult patients in the intensive care unit (ICU) (1-3). Propofol permits rapid awakening for frequent neurological examination (4). Despite this clinical advantage, a series of case reports have documented severe metabolic acidosis, cardiogenic shock, and death in pediatric ICU patients on prolonged propofol infusion (5-14). Although our patient presented in a similar fashion, he was managed early with mechanical circulatory support that allowed complete recovery. This highlights the unique life-saving application of extracorporeal circulation for cardiogenic shock associated with a prolonged propofol infusion.
P ropofol is one of the commonly accepted drugs administered as an infusion for the sedation of adult patients in the intensive care unit (ICU) (1) (2) (3) . Propofol permits rapid awakening for frequent neurological examination (4) . Despite this clinical advantage, a series of case reports have documented severe metabolic acidosis, cardiogenic shock, and death in pediatric ICU patients on prolonged propofol infusion (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . Although our patient presented in a similar fashion, he was managed early with mechanical circulatory support that allowed complete recovery. This highlights the unique life-saving application of extracorporeal circulation for cardiogenic shock associated with a prolonged propofol infusion.
Case Report
A 13-yr-old, 40-kg male with mild asthma presented with an acute intraventricular hemorrhage secondary to an arteriovenous malformation (AVM). The subsequent hydrocephalus was managed with a ventriculoperitoneal shunt. He made a full neurologic recovery. Approximately 6 wk after the original insult, the patient presented to our institution for elective craniotomy and resection of the 6 cm left parietal AVM.
In the operating room (OR), ASA routine monitors were placed and anesthesia was induced with propofol (100 mg, Diprivan ® ; AstraZeneca, Wilmington, DE) and fentanyl (50 g). The patient was in sinus rhythm with a normal QT interval. Neuromuscular blockade was obtained with titrated vecuronium; the train-of-four ratio (left ulnar nerve) was monitored throughout the entire case. After endotracheal intubation, a radial arterial line and large-bore peripheral venous access were placed. Initially, the patient was maintained on nitrous oxide (70%) and isoflurane (0.2%-0.5%), with titrated vecuronium to maintain the train-of-four ratio at 1/4. During the dissection of the AVM there was considerable bleeding and significant brain edema ensued. To facilitate brain relaxation, the head of the bed was further elevated, hyperventilation to a Pco 2 of 30 mm Hg was maintained, nitrous oxide was discontinued, and propofol (Diprivan ® ; AstraZeneca) was infused at 50 g · kg Ϫ1 · min
Ϫ1
. These intraoperative maneuvers facilitated further brain dissection, but severe intermittent bleeding continued. Hemostasis was achieved and further AVM resection was abandoned. The total operative time was 17 hours. Throughout the operation the mean arterial blood pressure (MAP) was 55-65 mm Hg. Intravascular volume resuscitation consisted of 6 L crystalloid, 13 U of packed red blood cells, 10 U of fresh-frozen plasma, and 12 U of platelets. Immediately after surgery, the patient underwent a computed tomographic scan of the brain; sedation was achieved with a propofol infusion at 140 g · kg Ϫ1 · min
. The patient was admitted to the neurosurgical ICU with adequate vital signs and was placed on mechanical ventilation. The patient was in sinus rhythm with a normal QT interval; the MAP was 60 mm Hg. Although there was no parenchymal bleeding on the recent CAT scan of the brain, there was significant brain edema. An intracranial pressure (ICP) monitor (Camino Laboratories, San Diego, CA) was placed within 30 min of ICU admission. To maintain an ICP Ͻ20 mm Hg, ICU maneuvers included:
• Elevation of the head of the patient's bed;
• Sedation with a propofol infusion titrated between 100 -190 g · kg Ϫ1 · min As the ICP was adequately controlled with these interventions, concomitant steroid administration or cerebrospinal fluid drainage was not added. Daily computed tomographic scans of the brain documented no new parenchymal brain pathology. Neurological examinations were performed during weaning of the propofol infusion to the point of patient comfort and response to verbal command. At 66 h after surgery, a prolonged QT interval and T wave inversions were noted on telemetry. Laboratory values at this time showed no change in serum electrolytes, acidbase status, or cardiac enzymes. At 74 h after surgery, hemodynamically unstable polymorphic ventricular tachycardia developed (Fig. 1) . The propofol infusion was discontinued. The ventricular tachycardia was managed with immediate cardioversion, IV magnesium and potassium supplementation, as well as infusions of lidocaine and amiodarone. Because of increasing pharmacologic circulatory support, an emergent transthoracic echocardiogram (TTE) was obtained. This revealed severe biventricular dysfunction, no pericardial effusion, and no significant valvular disease.
The patient continued to deteriorate because of persistent ventricular tachycardia refractory to cardioversion, lidocaine, and amiodarone. Cardiogenic shock ensued: it became refractory to infusions of epinephrine (8 g/min) and norepinephrine (10 g/min). Systolic blood pressures ranged from 60 -80 mm Hg, ICP was 35 mm Hg, and central venous pressure was 38 mm Hg. Blood chemistry revealed severe metabolic acidosis with a bicarbonate level of 9 mmol/L despite aggressive bicarbonate replacement. The patient also became oliguric, and the peak creatinine was 3.0 mg/ dL. The metabolic acidosis only began with the onset of biventricular dysfunction (inadequate tissue perfusion), and was subsequently aggravated by renal failure (inadequate acid clearance). There was biochemical evidence of rhabdomyolysis, as reflected by a creatine kinase in the thousands. The cardiac enzymes, including troponin and creatine kinase MB isoenzyme, were within normal limits. The chest film showed pulmonary edema.
Urgent cardiothoracic surgical consultation was obtained for consideration of mechanical circulatory support because of refractory cardiogenic shock. Despite the increased risk of intracranial bleeding from heparinization, it was decided that the best survival strategy was to proceed with mechanical circulatory support. Extracorporeal circulation with membrane oxygenation (ECMO) was instituted emergently at the bedside (Fig. 2) .
ECMO was initiated via the left femoral vessels. Because of the narrow caliber of the femoral artery, arterial perfusion of the left lower extremity via a smaller cannula was added to avoid left lower extremity ischemia. ECMO flows were maintained at 3.7-4.5 L/min and the activated clotting time was maintained between 150 -180 s with titrated heparin. Pharmacologic support of the circulation was discontinued. The patient remained oliguric, despite normalization of cardiac index. The renal failure was felt to be attributable to continuing rhabdomyolysis with myoglobinuria, as well as hemolysis from exposure to the ECMO circuit. The patient had a mild unconjugated hyperbilirubinemia (2-3 mg/dL), consistent with continuing hemolysis. The hemoglobin was maintained in the 9 -10 g/dL range with transfusion of 1-2 U of packed red blood cells every 24 h. To prevent fluid overload, the patient was dialyzed by means of a dialysis filter connected into the ECMO circuit.
Twenty-four hours later, the patient continued to have biventricular failure by TTE and accelerated junctional tachycardia. Forty-eight hours later, the patient demonstrated marked improvement, with native cardiac ejection and normalization of cardiac rhythm (Fig. 3) . TTE now demonstrated normal biventricular function, even when ECMO support was temporarily weaned. Sixty hours after its institution, ECMO was successfully discontinued in the OR. Normal biventricular function was confirmed by intraoperative transesophageal echocardiography. The left femoral artery was repaired, with no ischemia of the left lower extremity.
The remaining hospital course was uneventful. The patient continued to improve neurologically. Mechanical ventilation was discontinued on postoperative day 19. He was discharged to a rehabilitation facility on postoperative day 28. The patient was in sinus rhythm with a normal QT interval. He made a full recovery and returned to school.
Discussion
This is the first report of survival with mechanical circulatory support after cardiogenic shock associated with propofol infusion. Propofol (2,6-diisopropylphenol) is an IV sedative/hypnotic for the induction/maintenance of anesthesia and continuous sedation in the ICU. The formulations of propofol available in the United States are Diprivan ® (AstraZeneca Pharmaceuticals) and propofol (Baxter Pharmaceutical Products, Inc., New Providence, NJ). The generic formulation of propofol incorporates sodium metabisulfite (0.25 mg/mL) as the preservative and has a lower pH (4.5-6.4) (15). Diprivan ® uses the preservative disodium edentate (0.005%) with sodium hydroxide to adjust to a pH of 7-8.5 (16) . The lower pH of the generic propofol has been linked to significant clinical metabolic acidosis in a patient on a prolonged infusion (17) . Our institution uses Diprivan ® ; all references to propofol in this article imply the Diprivan ® formulation. The effect of propofol is dose-dependent: infusion rates are titrated to clinical effect (18) with a rapid onset and short duration (19) . The Food and Drug Administration approved propofol for ICU sedation by 1993. In the neurosurgical ICU, sedation is important to facilitate mechanical ventilation as well as to avoid increases in MAP and ICP in response to stimuli (20) . In a prospective, randomized, double-blind clinical trial, Kelly et al. (21) demonstrated that a propofol-based sedation and ICP control regimen is a safe and effective alternative to an opiate-based regimen in the head-injured patient. In addition to the benefit of rapid awakening for frequent neurological examination, propofol confers neuroprotective effects by decreasing cerebral metabolic rate, potentiating ␥-aminobuturate A inhibition, and inhibiting methyl-D-aspartate glutamate receptors and voltage-dependent calcium channels (22) . The main risks of propofol infusion include respiratory depression (23) , hypotension (24) , bradycardia (25, 26) , arrhythmias (27) , infection (28), hyperlipidemia (29) , and pain on injection (30) .
There is controversy in the literature regarding the safety of propofol for continuous sedation in the pediatric ICU population. Although many authors report no adverse effects (31) (32) (33) (34) , the drug manufacturer clearly states that propofol is not indicated for use in pediatric ICU sedation because the safety of this regimen has not been established (16) .
In our review of the literature, we identified several case reports in which pediatric ICU patients on a prolonged propofol infusion experienced adverse effects (Table 1) (5-14). These cases have the following features in common: large dosage (mean, 140 g · kg Ϫ1 · min
Ϫ1
), prolonged duration of infusion (mean, 68 hours), severe metabolic acidosis, significant arrhythmias, ventricular failure, and death.
Although there is no proven causative relationship, this phenomenon has been labeled the "propofol infusion syndrome" (13, 37) . The syndrome occurs in the susceptible pediatric patient who has received a propofol dose in excess of 67 g · kg Ϫ1 · min Ϫ1 for at least 48 hours. The clinical features include acute refractory bradycardia with asystole and the presence of one or more of the following: lipemic plasma, clinically enlarged liver/or fatty liver at autopsy, metabolic acidosis with a base deficit Ͼ10, or muscle involvement with evidence of rhabdomyolysis or myoglobinuria (35) .
Although the mechanism for this syndrome remains elusive, it is probably multifactorial. Several hypotheses regarding the adverse cardiac effects of the drug have been proposed. Propofol is associated with bradycardia (25, 26) . Propofol reduces sympathetic tone more than parasympathetic tone, thus resulting in bradycardia from an unopposed parasympathetic response (25) . In rat models, Zhou et al. (36, 37) have demonstrated that propofol is a cardiac depressant by the mechanisms of MA ϭ metabolic acidosis; BC ϭ bradycardia; Asys ϭ Asystole; Echo ϭ Echocardiography; PR ϭ pharmacologic resuscitation; CVVH ϭ continuous veno-veno hemodialysis; VT/VF ϭ ventricular tachycardia/fibrillation; RBBB ϭ right bundle branch block; RF ϭ renal failure; ECMO ϭ extra corporal membrane oxygenation; AVM ϭ arteriovenous malformation.
antagonism of ␤-receptors and calcium channel binding with resulting decrease in myocardial contractility. Propofol also affects mitochondrial performance: it depresses mitochondrial oxidative phosphorylation and hence total energy production, as reflected by adenosine triphosphate metabolism (38) . This interference with mitochondrial performance impairs oxygen and electron kinetics in the myocyte and hence depresses myocardial contractility (39) . Furthermore, the ventricular arrhythmias in our patient may have been the result of high circulating levels of fatty acids as a consequence of impaired mitochondrial oxidation in the presence of large serum concentrations of propofol (13, 40) . Excess serum fatty acids have proarrhythmic effects that are responsible for ventricular arrhythmias (40) . Thus, there is evidence linking propofol to ventricular dysfunction and ventricular arrhythmias on the basis of mitochondrial dysfunction.
Our 13-year-old patient meets the definition of propofol infusion syndrome with respect to dose, duration, myocardial failure, and metabolic acidosis. The majority of children in the published literature died from myocardial failure. The common feature of those that survived was early hemodialysis (6, 9, 12, 13) . This response to dialysis suggests a possible metabolic mechanism. Our child also survived and eventually made a full neurologic recovery. We attribute this outcome to early institution of mechanical circulatory support via the use of ECMO. This bedside mechanical circulatory support allowed immediate patient survival and further time to assess whether the myocardium would recover. The relatively short time for total myocardial recovery allowed prompt withdrawal of ECMO. If there had been delayed myocardial recovery, then prolonged ECMO or perhaps even a ventricular-assist device might have had to be considered.
Conclusions
We conclude that despite the series of case reports, no causative relationship between prolonged propofol infusion and myocardial failure has been proven. However, the manufacturer does caution against propofol for pediatric ICU sedation (16) . The cardiogenic shock in our patient was refractory to aggressive medical therapy. The prompt institution of ECMO was lifesaving in this patient because it gave the heart time to recover.
